Neridronic acid - Abiogen Pharma

Drug Profile

Neridronic acid - Abiogen Pharma

Alternative Names: AHBP; AHDP; AHHexBP; Aminohexane diphosphonate; Aminohexane-bisphosphonate; Attila; Neridronate; Neridronate-sodium; Nerixia

Latest Information Update: 19 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Istituto Gentili
  • Developer Abiogen Pharma; Austin Pain Associates; Grunenthal; Lees Pharmaceutical Holdings; Shire Pharmaceuticals Group
  • Class Bisphosphonates; Calcium regulators; Small molecules
  • Mechanism of Action Bone resorption factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Reflex sympathetic dystrophy
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Osteitis deformans; Osteogenesis imperfecta
  • Registered Complex regional pain syndromes
  • Discontinued Malignant hypercalcaemia; Postmenopausal osteoporosis

Most Recent Events

  • 13 Jun 2018 Phase-III clinical trials in Complex regional pain syndromes in Asia and European Union (IV)
  • 21 May 2018 Grunenthal initiates a phase III trial for Complex regional pain syndromes in USA (IV) (NCT03530345)
  • 21 May 2018 Grunenthal plans a phase III trial for Complex regional pain syndromes in USA (IV) (NCT03530345)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top